Creative Biogene Optimizes Kinase Screening and Profiling Services to Accelerate Precision Drug Discovery

Creative Biogene, a global leader in scientific testing and laboratory services for advancement of drug discovery and human health, providing products and services have enabled thousands of researchers to advance biological discoveries across a wide variety of disciplines. Recently, Creative Biogene announced the optimization of its comprehensive Kinase Screening and Profiling Services with largest collection of biochemical and cell-based kinase assays, including unique assays that allow rapid determination of kinome-wide compound potency and selectivity.

Designed specifically to empower pharmaceutical companies and academic institutions, the enhanced service suite enables researchers to swiftly identify potent and selective kinase inhibitors, ultimately driving the development of safer, highly effective therapeutic candidates.

Kinases represent one of the most critical and expansive superfamilies of druggable targets, playing a primary role in regulating cell proliferation, metabolism, and death. Creative Biogene offers various platforms of biochemical and cell-based kinase assays that enable development of entire kinase drug discovery programs — from HTS screens to Hit-to-Lead and Lead Optimization. Creative Biogene is capable to set up a complete screening cascade for efficient, rapid and affordable outcome programs, leading to the selection of potent and selective lead candidates targeting kinases of interest.

Besides, Creative Biogene effectively addresses the common challenges in kinase drug development by providing an unparalleled suite of customized solutions. By collaborating with Creative Biogene, clients can efficiently navigate the complexities of kinase drug development, gain a deeper understanding of structure-activity relationships, and avoid targets with toxic risks. This ensures that only the most promising and feasible drug candidates enter the development process, significantly reducing development time and overall financial investment.

"Our primary mission is to help our customers achieve their most ambitious drug discovery goals with confidence and unprecedented speed," said Marcia Brady, official spokesperson for Creative Biogene. "Developing selective kinase inhibitors is a notorious challenge due to off-target effects. By utilizing our comprehensive biochemical and cell-based assay platforms, we provide researchers with the exact data they need to make highly informed decisions. We don't just supply a service; we act as an extension of our clients' teams to help bring life-saving therapies to market faster."  

To deliver these robust results, Creative Biogene leverages a diverse array of advanced technological platforms. Working with an experienced team provides customers the benefit of screening compounds against the largest panel of unique wild-type human kinases available, and enables customers to make better-informed decisions about therapeutic opportunities and potential off-target liabilities that could be otherwise missed in smaller kinase panels. Coupled with the fastest turnaround time in the industry, Creative Biogene’s Kinase Screening and Profiling Services enable expeditious SAR analysis to advance those compounds with the highest chance of being clinically effective and safe – as quickly as possible.

Beyond specialized screening services, Creative Biogene comprehensively supports clients by supplying a vast portfolio of kinase gene-related products. This includes stable cell lines, premade virus particles, cell lysates, clone products, and RNAi products, ensuring researchers have continuous access to high-quality materials from a single, trusted vendor.  

About Creative Biogene

Creative Biogene is a leading biotechnology provider dedicated to delivering high-quality products and flexible services for life science research. Creative Biogene offers a broad portfolio of services and a global network of partners that enable us to provide end-to-end service for diverse research, combined with an agile science-focused culture that delivers the same high quality of data for projects of any size.